📣 VC round data is live. Check it out!

GRAIL Valuation Multiples

Discover revenue and EBITDA valuation multiples for GRAIL and similar public comparables like Dr. Lal PathLabs, HeartFlow, Insight Lifetech, Telix Pharmaceuticals and more.

GRAIL Overview

About GRAIL

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.


Founded

2015

HQ

United States

Employees

1.0K

Website

grail.com

Financials (LTM)

Revenue: $161M
EBITDA: ($352M)

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

GRAIL Financials

GRAIL reported last 12-month revenue of $161M and negative EBITDA of ($352M).

In the same LTM period, GRAIL generated ($15M) in gross profit, ($352M) in EBITDA losses, and had net loss of ($417M).

Revenue (LTM)


GRAIL P&L

In the most recent fiscal year, GRAIL reported revenue of $147M and EBITDA of ($378M).

GRAIL is unprofitable as of last fiscal year, with gross margin of (43%), EBITDA margin of (257%), and net margin of (277%).

See analyst estimates for GRAIL
LTMLast FY202320242025202620272028
Revenue$161M$147M$56M$126M$147M
Gross Profit($15M)($63M)($116M)($78M)($63M)
Gross Margin(10%)(43%)(210%)(62%)(43%)
EBITDA($352M)($378M)($588M)($610M)($378M)
EBITDA Margin(219%)(257%)(1058%)(486%)(257%)
EBIT Margin(305%)(330%)(1337%)(612%)(363%)
Net Profit($417M)($408M)($5B)($2B)($408M)
Net Margin(260%)(277%)(9719%)(1614%)(277%)

Financial data powered by Morningstar, Inc.

GRAIL Stock Performance

GRAIL has current market cap of $3B, and enterprise value of $2B.

Market Cap Evolution


GRAIL's stock price is $64.40.

GRAIL share price decreased by 10.2% in the last 30 days, and increased by 25.2% in the last year.

GRAIL has an EPS (earnings per share) of $-9.51.

See more trading valuation data for GRAIL
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$3B-10.2%-10.2%24.6%25.2%$-9.51

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

GRAIL Valuation Multiples

GRAIL trades at 12.4x EV/Revenue multiple, and (5.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for GRAIL

EV / Revenue (LTM)


GRAIL Financial Valuation Multiples

As of June 2, 2026, GRAIL has market cap of $3B and EV of $2B.

GRAIL has a P/E ratio of (6.6x).

LTMLast FY202320242025202620272028
EV/Revenue12.4x13.5x35.9x15.9x13.5x
EV/EBITDA(5.7x)(5.3x)(3.4x)(3.3x)(5.3x)
EV/EBIT(4.1x)(4.1x)(2.7x)(2.6x)(3.7x)
EV/Gross Profit(130.3x)(31.8x)(17.1x)(25.5x)(31.8x)
P/E(6.6x)(6.8x)(0.5x)(1.4x)(6.8x)
EV/FCF(6.8x)(6.6x)(3.4x)(3.4x)(6.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified GRAIL Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

GRAIL Margins & Growth Rates

GRAIL grew revenue by 22% but EBITDA decreased by 20% in the last fiscal year.

In the most recent fiscal year, GRAIL reported gross margin of (43%), EBITDA margin of (257%), and net margin of (277%).

See estimated margins and future growth rates for GRAIL

GRAIL Margins

Last FY202420252026202720282029
Gross Margin(43%)(62%)(43%)(13%)
EBITDA Margin(257%)(486%)(257%)(168%)
EBIT Margin(330%)(612%)(363%)(277%)
Net Margin(277%)(1614%)(277%)(239%)
FCF Margin(204%)(464%)(204%)(159%)

GRAIL Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth22%126%17%22%
Gross Profit Growth(61%)(33%)(20%)(61%)
EBITDA Growth(20%)4%(38%)(20%)
EBIT Growth2%3%(30%)(7%)
Net Profit Growth5%(62%)(80%)5%
FCF Growth(5%)(0%)(49%)(5%)

Data powered by FactSet, Inc. and Morningstar, Inc.

GRAIL Operational KPIs

GRAIL's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.5M for the same period.

GRAIL's Rule of 40 is (146%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

GRAIL's Rule of X is (113%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for GRAIL
LTMLast FY202320242025202620272028
Rule of 40(195%)(146%)---
Bessemer Rule of X(160%)(113%)---
Revenue per Employee-$0.1M---
Opex per Employee-$0.5M---
S&M Expenses to Revenue74%80%220%123%79%
G&A Expenses to Revenue98%113%313%170%108%
R&D Expenses to Revenue115%134%593%257%133%
Opex to Revenue-320%1127%550%320%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Dr. Lal PathLabs10.2x8.9x31.9x31.4x
HeartFlow14.4x12.8x(76.6x)(65.9x)
Insight Lifetech29.3x-131.9x-
Telix Pharmaceuticals4.3x4.0x80.4x69.4x
BGI Genomics3.4x3.3x42.7x39.0x
Genus2.6x2.6x14.5x13.2x
10x Genomics5.1x5.2x843.7x(71.8x)
Veracyte6.7x6.3x24.2x23.3x

This data is available for Pro users. Sign up to see all GRAIL competitors and their valuation data.

Start Free Trial

GRAIL VC Funding History

Before going public, GRAIL raised $2B in total equity funding, across 4 rounds.

Last private valuation of GRAIL was $6B, after raising $390M in May 2020 from CPP Investments, Huangpu River Capital, Illumina, and 1 other investor.


GRAIL Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
May-20Series DCPP Investments; Huangpu River Capital; Illumina; PSP Investments$390M$6BGRAIL, Inc., a Menlo Park, California-based healthcare company spun out from Illumina, develops a blood-based multi-cancer early detection test using methylation-based next-generation sequencing and machine learning to detect over 50 cancer types and identify tumor origin with low false positives. The company announced a $390 million Series D financing on May 6, 2020, led by new investors Public Sector Pension Investment Board (PSP Investments) and Canada Pension Plan Investment Board (CPP Investments), plus two undisclosed investors and existing backer Illumina. This round brought GRAIL's total equity financing since 2016 to over $1.9 billion across four rounds, funding massive clinical trials like PATHFINDER, the first to return test results to participants for diagnostic workups. The proceeds supported continued development and commercialization of GRAIL's Galleri test, planned for a 2021 launch as a laboratory-developed test, amid progress in population-scale studies to reduce cancer mortality. Investors recognized GRAIL's advancements in detecting cancers lacking screening tests, where nearly 80% of deaths occur. The funding aligned with prior rounds, including a $300 million oversubscribed Series C in 2019 led by Ally Bridge Group with Huangpu River Capital and others, building toward Grail's IPO filing later in 2020.
May-18Series C6 Dimensions Capital; Ally Bridge Group; Blue Pool Capital; China Merchants Securities; Genuity Science; Hillhouse Investment; HSG; Huangpu River Capital; ICBC International$300M--
Mar-17Series BAmino Capital; ARCH Venture Partners; Glen Kacher; Johnson & Johnson Development Corporation; The Mark Foundation for Cancer Research$1B-GRAIL, a life sciences company focused on early cancer detection through blood tests, closed over $900 million in the first tranche of its Series B financing on March 1-2, 2017, led by ARCH Venture Partners with participation from Johnson & Johnson Innovation (via affiliate), Amazon, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck, Tencent Holdings, and Varian Medical Systems. The company planned a second close to reach over $1 billion total by end of Q1 2017, with Goldman Sachs as placement agent. Proceeds were allocated to product development, validation of early-stage cancer detection tests, large-scale clinical trials like the Circulating Cell-free Genome Atlas study, and repurchasing part of Illumina's stake, reducing Illumina's ownership to slightly less than 20%. This followed GRAIL's Series A of over $100 million from Illumina, ARCH Venture Partners, Bezos Expeditions, Bill Gates, Sutter Hill Ventures, and GV. The investors highlighted GRAIL's progress in high-intensity sequencing, population-scale studies, and data science for noninvasive cancer screening.
Jan-16Series AARCH Venture Partners; Bezos Expeditions; Bill Gates; Biomatics Capital Partners; GV; Illumina; Longwood Fund; Sutter Hill Ventures$100M-GRAIL, a cancer screening technology startup spun out from Illumina, raised over $100 million (subsequently increased to $125 million) in a Series A round in January 2016, co-led by Illumina and ARCH Venture Partners, with participation from Bezos Expeditions, Bill Gates, and Sutter Hill Ventures. Illumina retained a majority stake in GRAIL, which is developing blood tests for early cancer detection without symptoms. The funding supported initial development of high-intensity sequencing technology leveraging Illumina's platforms. This Series A marked the launch of GRAIL as an independent entity focused on population-scale clinical trials and multi-cancer early detection via cell-free DNA analysis. The round positioned GRAIL to pursue ambitious goals in oncology screening. Subsequent rounds built on this foundation: a Series B in March 2017 raised over $900 million led by ARCH Venture Partners with investors including Johnson & Johnson Innovation, Amazon, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck, Tencent, and Varian; some proceeds repurchased part of Illumina's stake, reducing it to under 20%. By 2020, GRAIL had raised nearly $2 billion across four rounds, culminating in Illumina's $8 billion acquisition, buying out remaining shares beyond its 14.5% holding.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About GRAIL

When was GRAIL founded?GRAIL was founded in 2015.
Where is GRAIL headquartered?GRAIL is headquartered in United States.
How many employees does GRAIL have?As of today, GRAIL has over 1K employees.
Who is the CEO of GRAIL?GRAIL's CEO is Robert Ragusa.
Is GRAIL publicly listed?Yes, GRAIL is a public company listed on Nasdaq.
What is the stock symbol of GRAIL?GRAIL trades under GRAL ticker.
When did GRAIL go public?GRAIL went public in 2024.
Who are competitors of GRAIL?GRAIL main competitors include Dr. Lal PathLabs, HeartFlow, Insight Lifetech, Telix Pharmaceuticals, BGI Genomics, Genus, 10x Genomics, Veracyte, Diasorin, Fleury.
What is the current market cap of GRAIL?GRAIL's current market cap is $3B.
What is the current revenue of GRAIL?GRAIL's last 12 months revenue is $161M.
What is the current revenue growth of GRAIL?GRAIL revenue growth (NTM/LTM) is 24%.
What is the current EV/Revenue multiple of GRAIL?Current revenue multiple of GRAIL is 12.4x.
Is GRAIL profitable?No, GRAIL is not profitable.
What is the current EBITDA of GRAIL?GRAIL has negative EBITDA and is not profitable.
What is GRAIL's EBITDA margin?GRAIL's last 12 months EBITDA margin is (219%).
What is the current EV/EBITDA multiple of GRAIL?Current EBITDA multiple of GRAIL is (5.7x).
What is the current FCF of GRAIL?GRAIL's last 12 months FCF is ($295M).
What is GRAIL's FCF margin?GRAIL's last 12 months FCF margin is (183%).
What is the current EV/FCF multiple of GRAIL?Current FCF multiple of GRAIL is (6.8x).
How many companies GRAIL has acquired to date?GRAIL hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies GRAIL has invested to date?GRAIL hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to GRAIL

Lists including GRAIL

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial